Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose
Mol Pharmacol 1997
Food and Drug Administration (FDA) in 2002 for the treatment of advanced hormone receptor-positive breast cancer, marking the advent of a new era in endocrine therapy
Front Oncol (2021) 11:783067
You might experience a little mild soreness or redness at the injection site, but this usually fades within a day
But the good news is we have tested this treatment intravenously as well, and theres no sign of any toxicity, no sign of tumors at all after a year in mice, just blasting these genes but instead of three weeks which we do in the eye, blasting it for a year
